Managing Pharmaceutical Costs in Health Systems: A Review of Affordability, Accessibility and Sustainability Strategies
2024

Managing Pharmaceutical Costs in Health Systems

Sample size: 390465 publication Evidence: low

Author Information

Author(s): Ntais Christos, Talias Michael A., Fanourgiakis John, Kontodimopoulos Nikolaos

Primary Institution: Open University of Cyprus

Hypothesis

This study reviews specific worldwide policies aimed at reducing drug-related spending and/or increasing the efficiency of pharmaceutical use.

Conclusion

Policymakers frequently enact numerous laws and regulations to control pharmaceutical expenditure, even if there is limited evidence that they are cost-effective.

Supporting Evidence

  • Governments worldwide have implemented a great variety of policy measures to manage pharmaceutical expenditure while ensuring fair access to essential medicines.
  • Cost-sharing schemes, value-based pricing, reimbursement, reference pricing, payback mechanisms and the substitution of original drugs with generics and biosimilars are pivotal in these efforts.
  • Overall, it appears that any gains may be outweighed by the unfavorable effects of policies impacting patients.
  • Further research is needed to develop context-specific guidance that balances cost containment, equity and sustainability.

Takeaway

This study looks at how different countries try to save money on medicines while making sure people can still get the drugs they need. Sometimes, these money-saving plans can make it harder for people to get their medicines.

Methodology

The method used was the narrative literature review of studies which assessed the effect of pharmaceutical cost containment policies.

Potential Biases

The inclusion of studies was guided by relevance to the objectives, and all four authors critically reviewed interpretations to ensure balanced perspectives.

Limitations

As a narrative review, this study is inherently susceptible to selection bias.

Participant Demographics

The study involved four cohorts of regular users of medications and a random sample of the Medicaid population.

Digital Object Identifier (DOI)

10.3390/jmahp12040031

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication